Antisense compounds, compositions and methods are provided for modulating the expression of PI3 kinase p110 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p110 beta. Methods of using these compounds for modulation of PI3 kinase p110 beta expression and for treatment of diseases associated with expression of PI3 kinase p110 beta are provided.
Claims What is claimed is: 1. An antisense compound 8 to 30 nucleobases in length targeted to a start codon or nucleobases 4-3174 of the coding region of human PI3 kinase p110 beta, wherein said antisense compound specifically hybridizes with and inhibits the expression of human PI3 kinase p110 beta. 2. The antisense compound of claim 1 which is an antisense oligonucleotide. 3. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 4. The antisense compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage. 5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 6. The antisense compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 8. The antisense compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine. 9. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 10. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 11. The composition of claim 10 further comprising a colloidal dispersion system. 12. The composition of claim 10 wherein the antisense compound is an antisense oligonucleotide. 13. A method of inhibiting the expression of human PI3 kinase p110 beta in human cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of human P13 kinase p110 beta is inhibited. 14. An antisense compound up to 30 nucleobases in length targeted to a nucleic acid molecule encoding human PI3 kinase p110 beta and comprising at least an 8 nucleobase portion of SEQ ID NO: 11, 16, 19, 20, 26, 30, 35, 44, 8, 9, 10, 12, 13, 17, 18, 21, 22, 23, 24, 25, 27, 28, 29, 32, 33, 34, 36, 37, 38, 40, 43, 46 or 47, wherein said antisense compound specifically hybridizes with and inhibits the expression of human PI3 kinase p110 beta. 15. The antisense compound of claim 14 which is an antisense oligonucleotide. 16. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The antisense compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The antisense compound of claim 18 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The antisense compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The antisense compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A method of inhibiting the expression of human PI3 kinase p110 beta in human cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 14 so that expression of human PI3 kinase p110 beta is inhibited. 24. An antisense compound consisting of SEQ ID NO:14, wherein said antisense compound specifically hybridizes with and inhibits the expression of human PI3 kinase p110 beta. 